The Piramal Group on Monday announced that a Rs 110-crore investment into Biodeal Pharmaceuticals. According to the company’s statement, the contract development and manufacturing company will deploy the funds infused by Piramal Alternatives for improving its infrastructure and capacities, technology upgrade and a nutraceuticals manufacturing facility.
The company stated that the infusion is done through convertible instruments from Piramal Alternatives’ Performing Credit Fund.
The Piramal group statement said Biodeal is among India’s leading manufacturer of nasal sprays catering to marquee international and domestic pharmaceutical companies.
Piramal Alternatives’ chief executive Kalpesh Kikani said the market potential in the nasal sprays segment is strong, and pointed to Biodeal’s leading position in contract manufacturing and adherence to global regulatory standards as aspects which make it into an exciting opportunity.
Biodeal’s managing director Anurag Kumar said the fundraise will help it boost the production capacity by three times, be ready with a new upcoming facility in compliance with United States Food and Drug Administration (USFDA) accreditations in coming 12-15 months and expand its market reach, as reported by PTI.
